Delayed remission following sequential infusion of humanized CD19- and CD22-modified CAR-T cells in a patient with relapsed/refractory acute lymphoblastic leukemia and prior exposure to murine-derived CD19-directed CAR-T cells

BACKGROUND: CD19-modified CAR-T cells greatly influence responses in patients with relapsed/refractory acute lymphoblastic leukemia (ALL). However, recurrence remains a challenge, and reinfusion of CAR-T cells is not always effective. Sequential infusion of humanized CD19-modified and CD22-modified...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Fei, Zhang, Jian, Zhang, Xinyou, Tian, Mengli, Wang, Jingjing, Kang, Liqing, Qiu, Huiying, Wu, Depei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6438143/
https://www.ncbi.nlm.nih.gov/pubmed/30988623
http://dx.doi.org/10.2147/OTT.S189103
_version_ 1783407066390462464
author Yang, Fei
Zhang, Jian
Zhang, Xinyou
Tian, Mengli
Wang, Jingjing
Kang, Liqing
Qiu, Huiying
Wu, Depei
author_facet Yang, Fei
Zhang, Jian
Zhang, Xinyou
Tian, Mengli
Wang, Jingjing
Kang, Liqing
Qiu, Huiying
Wu, Depei
author_sort Yang, Fei
collection PubMed
description BACKGROUND: CD19-modified CAR-T cells greatly influence responses in patients with relapsed/refractory acute lymphoblastic leukemia (ALL). However, recurrence remains a challenge, and reinfusion of CAR-T cells is not always effective. Sequential infusion of humanized CD19-modified and CD22-modified CAR-T cells may overcome this issue and induce remission. METHODS: We examined treatment with sequential infusion of humanized CD19-modified and CD22-modified CAR-T cells in a patient with relapsed ALL previously exposed to murine-derived anti-CD19 CAR-T cells. RESULTS: At ~6 weeks after treatment, repeated bone marrow smear and flow cytometry analysis revealed no lymphoblasts. CONCLUSION: Our results suggest that sequential infusion of humanized CD19-modified and CD22-modified CAR-T cells is a valuable option for relapsed patients with prior infusion of murine-derived, CD19-directed CAR-T cells.
format Online
Article
Text
id pubmed-6438143
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-64381432019-04-15 Delayed remission following sequential infusion of humanized CD19- and CD22-modified CAR-T cells in a patient with relapsed/refractory acute lymphoblastic leukemia and prior exposure to murine-derived CD19-directed CAR-T cells Yang, Fei Zhang, Jian Zhang, Xinyou Tian, Mengli Wang, Jingjing Kang, Liqing Qiu, Huiying Wu, Depei Onco Targets Ther Original Research BACKGROUND: CD19-modified CAR-T cells greatly influence responses in patients with relapsed/refractory acute lymphoblastic leukemia (ALL). However, recurrence remains a challenge, and reinfusion of CAR-T cells is not always effective. Sequential infusion of humanized CD19-modified and CD22-modified CAR-T cells may overcome this issue and induce remission. METHODS: We examined treatment with sequential infusion of humanized CD19-modified and CD22-modified CAR-T cells in a patient with relapsed ALL previously exposed to murine-derived anti-CD19 CAR-T cells. RESULTS: At ~6 weeks after treatment, repeated bone marrow smear and flow cytometry analysis revealed no lymphoblasts. CONCLUSION: Our results suggest that sequential infusion of humanized CD19-modified and CD22-modified CAR-T cells is a valuable option for relapsed patients with prior infusion of murine-derived, CD19-directed CAR-T cells. Dove Medical Press 2019-03-25 /pmc/articles/PMC6438143/ /pubmed/30988623 http://dx.doi.org/10.2147/OTT.S189103 Text en © 2019 Yang et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Yang, Fei
Zhang, Jian
Zhang, Xinyou
Tian, Mengli
Wang, Jingjing
Kang, Liqing
Qiu, Huiying
Wu, Depei
Delayed remission following sequential infusion of humanized CD19- and CD22-modified CAR-T cells in a patient with relapsed/refractory acute lymphoblastic leukemia and prior exposure to murine-derived CD19-directed CAR-T cells
title Delayed remission following sequential infusion of humanized CD19- and CD22-modified CAR-T cells in a patient with relapsed/refractory acute lymphoblastic leukemia and prior exposure to murine-derived CD19-directed CAR-T cells
title_full Delayed remission following sequential infusion of humanized CD19- and CD22-modified CAR-T cells in a patient with relapsed/refractory acute lymphoblastic leukemia and prior exposure to murine-derived CD19-directed CAR-T cells
title_fullStr Delayed remission following sequential infusion of humanized CD19- and CD22-modified CAR-T cells in a patient with relapsed/refractory acute lymphoblastic leukemia and prior exposure to murine-derived CD19-directed CAR-T cells
title_full_unstemmed Delayed remission following sequential infusion of humanized CD19- and CD22-modified CAR-T cells in a patient with relapsed/refractory acute lymphoblastic leukemia and prior exposure to murine-derived CD19-directed CAR-T cells
title_short Delayed remission following sequential infusion of humanized CD19- and CD22-modified CAR-T cells in a patient with relapsed/refractory acute lymphoblastic leukemia and prior exposure to murine-derived CD19-directed CAR-T cells
title_sort delayed remission following sequential infusion of humanized cd19- and cd22-modified car-t cells in a patient with relapsed/refractory acute lymphoblastic leukemia and prior exposure to murine-derived cd19-directed car-t cells
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6438143/
https://www.ncbi.nlm.nih.gov/pubmed/30988623
http://dx.doi.org/10.2147/OTT.S189103
work_keys_str_mv AT yangfei delayedremissionfollowingsequentialinfusionofhumanizedcd19andcd22modifiedcartcellsinapatientwithrelapsedrefractoryacutelymphoblasticleukemiaandpriorexposuretomurinederivedcd19directedcartcells
AT zhangjian delayedremissionfollowingsequentialinfusionofhumanizedcd19andcd22modifiedcartcellsinapatientwithrelapsedrefractoryacutelymphoblasticleukemiaandpriorexposuretomurinederivedcd19directedcartcells
AT zhangxinyou delayedremissionfollowingsequentialinfusionofhumanizedcd19andcd22modifiedcartcellsinapatientwithrelapsedrefractoryacutelymphoblasticleukemiaandpriorexposuretomurinederivedcd19directedcartcells
AT tianmengli delayedremissionfollowingsequentialinfusionofhumanizedcd19andcd22modifiedcartcellsinapatientwithrelapsedrefractoryacutelymphoblasticleukemiaandpriorexposuretomurinederivedcd19directedcartcells
AT wangjingjing delayedremissionfollowingsequentialinfusionofhumanizedcd19andcd22modifiedcartcellsinapatientwithrelapsedrefractoryacutelymphoblasticleukemiaandpriorexposuretomurinederivedcd19directedcartcells
AT kangliqing delayedremissionfollowingsequentialinfusionofhumanizedcd19andcd22modifiedcartcellsinapatientwithrelapsedrefractoryacutelymphoblasticleukemiaandpriorexposuretomurinederivedcd19directedcartcells
AT qiuhuiying delayedremissionfollowingsequentialinfusionofhumanizedcd19andcd22modifiedcartcellsinapatientwithrelapsedrefractoryacutelymphoblasticleukemiaandpriorexposuretomurinederivedcd19directedcartcells
AT wudepei delayedremissionfollowingsequentialinfusionofhumanizedcd19andcd22modifiedcartcellsinapatientwithrelapsedrefractoryacutelymphoblasticleukemiaandpriorexposuretomurinederivedcd19directedcartcells

Ejemplares similares